| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Inhibition of the hedgehog pathway in advanced basal-cell carcinoma.
|
N Engl J Med
|
2009
|
8.55
|
|
2
|
Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449.
|
N Engl J Med
|
2009
|
7.23
|
|
3
|
Novel therapeutic inhibitors of the c-Met signaling pathway in cancer.
|
Clin Cancer Res
|
2009
|
3.11
|
|
4
|
First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement.
|
Cancer Discov
|
2013
|
2.88
|
|
5
|
Clinical experience of MEK inhibitors in cancer therapy.
|
Biochim Biophys Acta
|
2006
|
2.28
|
|
6
|
A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2.
|
Clin Cancer Res
|
2010
|
1.71
|
|
7
|
Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126.
|
Clin Cancer Res
|
2004
|
1.58
|
|
8
|
Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer.
|
Cancer Chemother Pharmacol
|
2012
|
1.57
|
|
9
|
Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells.
|
Clin Cancer Res
|
2010
|
1.42
|
|
10
|
Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma.
|
Cancer
|
2012
|
1.32
|
|
11
|
A first-in-human study of conatumumab in adult patients with advanced solid tumors.
|
Clin Cancer Res
|
2010
|
1.26
|
|
12
|
Phase 0 clinical trials: an answer to drug development stagnation?
|
J Clin Oncol
|
2009
|
1.26
|
|
13
|
Catabolic fate and pharmacokinetic characterization of trastuzumab emtansine (T-DM1): an emphasis on preclinical and clinical catabolism.
|
Curr Drug Metab
|
2012
|
1.12
|
|
14
|
Dermatologic side effects associated with gefitinib therapy: clinical experience and management.
|
Clin Lung Cancer
|
2003
|
1.05
|
|
15
|
Phase 1 first-in-human trial of the vascular disrupting agent plinabulin(NPI-2358) in patients with solid tumors or lymphomas.
|
Clin Cancer Res
|
2010
|
1.00
|
|
16
|
Advanced basal cell carcinoma of the skin: targeting the hedgehog pathway.
|
Curr Opin Oncol
|
2013
|
0.97
|
|
17
|
Phase I clinical trial of BMS-247550, a derivative of epothilone B, using accelerated titration 2B design.
|
Clin Cancer Res
|
2005
|
0.97
|
|
18
|
A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors.
|
Cancer Chemother Pharmacol
|
2014
|
0.92
|
|
19
|
Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer.
|
Invest New Drugs
|
2014
|
0.89
|
|
20
|
Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study.
|
Target Oncol
|
2014
|
0.88
|
|
21
|
Pulmonary metastasis of basal cell carcinoma: a rare manifestation of a common disease with variable clinical course.
|
J Thorac Oncol
|
2009
|
0.87
|
|
22
|
A phase 1 trial of XK469: toxicity profile of a selective topoisomerase IIbeta inhibitor.
|
Invest New Drugs
|
2006
|
0.85
|
|
23
|
Metabolic profile of XK469 (2(R)-[4-(7-chloro-2-quinoxalinyl)oxyphenoxy]-propionic acid; NSC698215) in patients and in vitro: low potential for active or toxic metabolites or for drug-drug interactions.
|
Cancer Chemother Pharmacol
|
2005
|
0.84
|
|
24
|
A phase II study of rebeccamycin analog (NSC-655649) in metastatic renal cell cancer.
|
Invest New Drugs
|
2003
|
0.82
|
|
25
|
Reducing undesirable hepatic clearance of a tumor-targeted vinca alkaloid via novel saccharopeptidic modifications.
|
J Pharmacol Exp Ther
|
2010
|
0.82
|
|
26
|
Phase I study of liposomal doxorubicin (Doxil) and cyclophosphamide in solid tumors.
|
Invest New Drugs
|
2005
|
0.82
|
|
27
|
Bioavailability and pharmacokinetics of the investigational anticancer agent XK469 (NSC 698215) in rats following oral and intravenous administration.
|
Cancer Chemother Pharmacol
|
2004
|
0.81
|
|
28
|
Phase I study of XL281 (BMS-908662), a potent oral RAF kinase inhibitor, in patients with advanced solid tumors.
|
Invest New Drugs
|
2014
|
0.81
|
|
29
|
Assessment of the drug interaction potential and single- and repeat-dose pharmacokinetics of the BRAF inhibitor dabrafenib.
|
J Clin Pharmacol
|
2014
|
0.80
|
|
30
|
A Phase I dose-escalation study of afatinib combined with nintedanib in patients with advanced solid tumors.
|
Future Oncol
|
2015
|
0.79
|
|
31
|
A comparison of the pharmacokinetics of the anticancer MET inhibitor foretinib free base tablet formulation to bisphosphate salt capsule formulation in patients with solid tumors.
|
Invest New Drugs
|
2010
|
0.79
|
|
32
|
Phase I dose-escalation study of the thioxanthone SR271425 administered intravenously once every 3 weeks in patients with advanced malignancies.
|
Invest New Drugs
|
2008
|
0.78
|
|
33
|
Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Metastatic Breast Cancer Previously Treated With Chemotherapy and 2 or More HER2-Targeted Agents: Results From the T-PAS Expanded Access Study.
|
Cancer J
|
2015
|
0.77
|
|
34
|
A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound, administered as a 24-h continuous infusion in patients with advanced solid tumors.
|
Cancer Chemother Pharmacol
|
2012
|
0.77
|
|
35
|
Phase I study of oral irinotecan as a single-agent and given sequentially with capecitabine.
|
Invest New Drugs
|
2010
|
0.77
|
|
36
|
Initial clinical sensitivity and acquired resistance to MET inhibition in MET-mutated papillary renal cell carcinoma.
|
J Clin Oncol
|
2013
|
0.76
|
|
37
|
The metabolism of pyrazoloacridine (NSC 366140) by cytochromes p450 and flavin monooxygenase in human liver microsomes.
|
Clin Cancer Res
|
2004
|
0.76
|
|
38
|
Phase I dose-escalation study of cabazitaxel administered in combination with gemcitabine in patients with metastatic or unresectable advanced solid malignancies.
|
Anticancer Drugs
|
2015
|
0.75
|
|
39
|
Theoretical and practical application of traditional and accelerated titration Phase I clinical trial designs: the Wayne State University experience.
|
J Biopharm Stat
|
2009
|
0.75
|
|
40
|
Brain natriuretic peptide: potential adjunct for cardiac risk assessment and management during treatment with experimental anticancer agents.
|
AAPS J
|
2007
|
0.75
|
|
41
|
A phase I study of oral ixabepilone in patients with advanced solid tumors.
|
Cancer Chemother Pharmacol
|
2014
|
0.75
|
|
42
|
Capecitabine and PPE syndrome: a case report.
|
Breast J
|
2003
|
0.75
|
|
43
|
In vitro and in vivo effects of acetyldinaline on murine megakaryocytopoiesis.
|
Cancer Chemother Pharmacol
|
2004
|
0.75
|